Sanofi makes moves in China
In the Wall Street Journal, Sanofi's R&D chief Marc Cluzel (photo) discusses the company's plans for expanding in China. Back in September Sanofi signed a deal to collaborate with the Chinese Academy of Medical Sciences on stem cell research. As many as five more deals will follow, though Cluzel declined to say which partners Sanofi has approached and how much money the company intends to invest in China. The company is hoping to work with universities and state-funded research institutions.
Despite recent concerns about the quality of Chinese-made medical products, the country is actively pursuing an increased role in biotech R&D. Cluzel says the talent pool and entrepreneurial spirit of Chinese researchers will help the country become a leader in the biotech industry. "I think the amount of people with a master's [degree] in biology in China is now bigger than the number of people with a master's in biology in the U.S. The number of people with a Ph.D. in biology in the U.S. is still higher than in China, but it's getting closer and closer," Dr. Cluzel said. "And they are doing some good fundamental science. One day or another there will be a payback."
- read the WSJ article for more
Related Articles:
Sanofi signs stem cell pact in China. Report
Sanofi to build vaccine plant in China. Report
China pushes drug development as R&D soars. Report
Comments
Why just China? What about other BRIC countries?
We shhould be very wary given China's record!
Cluzel has gone mad! Its not a pure numbers game!
Quantity over quality? I wonder if the same yardstick were to apply to Sanofi all its touted pipeline would account for zero drug approved!
Is that why the rush to China...cheap labor?
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


